Related Experiment Video
Updated: Jun 29, 2026
Pre-clinical Evaluation of Tyrosine Kinase Inhibitors for Treatment of Acute Leukemia
Published on: September 18, 2013
Incidence and Radiological Spectrum of Interstitial Lung Disease in Patients With Lung Cancer Treated With Tyrosine
Supantha De1, Prasanta R Mohapatra1, Mahismita Patro1
1Pulmonary Medicine and Critical Care, All India Institute of Medical Sciences, Bhubaneswar, Bhubaneswar, IND.
Abstract:
Background Tyrosine kinase inhibitors (TKIs) have improved outcomes in driver mutation-positive non-small cell lung cancer (NSCLC), yet drug-induced interstitial lung disease (ILD) remains an uncommon but clinically relevant toxicity. Objectives To determine the incidence and radiological spectrum of ILD among lung cancer patients receiving TKIs, describe accompanying adverse effects, identify clinical and treatment-related risk factors, and estimate progression-free survival (PFS). Methods This single-center observational study included consecutive mutation-positive lung cancer patients treated with TKIs between January 2024 and September 2025 at a tertiary institute in Eastern India. Baseline demographic, clinical, radiological, and molecular data were recorded. Patients were followed for 12 months with structured clinical assessment, laboratory monitoring, and imaging. ILD was classified as TKI-attributable or all-cause. Results Among 106 patients, most were aged 50 years or older (80.2%), male participants (54.7%), non-smokers (85.8%), and had advanced-stage disease (93.4%). Epidermal Growth Factor Receptor (EGFR) exon19 (50.9%) and exon21 (16.0%) mutations dominated in the group. Erlotinib (48.1%) and osimertinib (22.6%) were most frequently used. TKI-induced ILD occurred in 3.7% of patients, while all-cause ILD occurred in 16.0%. Radiologically, 95.3% of the study group showed no ILD pattern. Disease control was achieved in 68.8% of cases. Mean PFS was 10.4 ± 2.91 months, with a 12-month survival of 61.2%. Mild toxicities predominated; 84.0% had no Common Terminology Criteria for Adverse Events (CTCAE)-graded toxicity at one year. Smoking status correlated with treatment response (p=0.045), and Eastern Cooperative Oncology Group (ECOG) performance predicted PFS (p=0.048). No baseline factor independently predicted ILD. Conclusions TKIs demonstrated favorable disease control with low attributable ILD. Continued monitoring and structured risk assessment remain essential.
Insights
Tyrosine kinase inhibitors (TKIs) show effective disease control in lung cancer with a low incidence of drug-induced interstitial lung disease (ILD). Continued monitoring is essential for managing this uncommon toxicity.
Area of Science:
- Oncology
- Pulmonology
- Pharmacology
Background:
- Tyrosine kinase inhibitors (TKIs) have improved outcomes for driver mutation-positive non-small cell lung cancer (NSCLC).
- Drug-induced interstitial lung disease (ILD) is an uncommon but significant toxicity associated with TKIs.
- Understanding the incidence and characteristics of TKI-induced ILD is crucial for patient management.
Purpose of the Study:
- To determine the incidence and radiological spectrum of ILD in lung cancer patients receiving TKIs.
- To describe associated adverse effects and identify risk factors for ILD.
- To estimate progression-free survival (PFS) in this patient cohort.
Main Methods:
- Single-center observational study of 106 mutation-positive NSCLC patients treated with TKIs.
- Data collection included demographics, clinical, radiological, and molecular profiles.
- 12-month follow-up with clinical assessments, laboratory monitoring, and imaging.
Main Results:
- TKI-induced ILD occurred in 3.7% of patients; all-cause ILD was 16.0%.
- Most patients (80.2%) were aged 50+, 85.8% were non-smokers, and 93.4% had advanced disease.
- Disease control was achieved in 68.8%, with a mean PFS of 10.4 months and 61.2% 12-month survival.
Conclusions:
- TKIs offer favorable disease control in NSCLC with a low rate of TKI-attributable ILD.
- No baseline factor independently predicted ILD development.
- Ongoing monitoring and structured risk assessment are vital for patients on TKIs.
